Helen-Marie Dunmore is a principal scientific advisor who has significant experience with regulatory requirements in the nonclinical development of advanced therapy medicinal products (cell and gene therapies) and a wide range of large and small molecules.
Prior to joining Charles River, she served as a senior nonclinical assessor at the MHRA reviewing nonclinical data packages (pharmacology, toxicology, and toxicokinetic) submitted in support of clinical trial authorization applications (Phases I-IV) or marketing authorization applications across therapy areas.
Helen-Marie also has experience with presenting nonclinical findings and making recommendations to UK/EU Advisory Committees (e.g., CHM and CHMP) and providing scientific/regulatory advice (on behalf of the MHRA and/or CHMP) to various stakeholders. She was also involved in reviewing regulatory guidance and representing the MHRA on working groups.
Helen-Marie has a master’s degree in applied toxicology from the University of Surrey (United Kingdom) and is a registered toxicologist in the UK and Europe.